FRAMINGHAM, Mass.--(BUSINESS WIRE)--GTC Biotherapeutics, Inc. (“GTC”, NASDAQ: GTCB) has received a Staff Deficiency Letter from The NASDAQ Stock Market notifying GTC that for the 10 consecutive trading days the aggregate market value of GTCB common stock has fallen below $35 million, the minimum level required for continued listing on The NASDAQ Capital Market, as specified by the Marketplace Rule 4310(c)(3)(B).
